Verrica Pharmaceuticals (VRCA) Jefferies Global Healthcare Conference 2025 summary

Company overview and product focus

• Focuses on dermatology with YCANTH, an in-office treatment for molluscum contagiosum, launched July last year.

• YCANTH addresses a large unmet need in pediatric molluscum, a contagious skin disease with no prior commercial treatments.

• The company restructured its commercial strategy and management team in late 2023.

• Pipeline includes phase III plans for common warts with a Japanese partner and a phase II asset for basal cell carcinoma.

• Japanese partner Torii filed for approval of YCANTH in Japan, with potential approval this year.

Clinical efficacy and feedback

• YCANTH achieves rapid lesion clearance, with most patients seeing substantial results after two to three treatments.

• Phase III studies exceeded FDA's 100% clearance goal, showing robust efficacy and safety.

• Clinical data showed an 80% reduction in lesions versus placebo over 12 weeks.

• Repeat administration every three weeks is typical due to the virus's incubation period.

• Clinicians report high satisfaction with both efficacy and safety.

Market access, reimbursement, and distribution

• Initial reimbursement challenges addressed by securing a permanent J-code in Q3 last year.

• Shifted from a buy-and-bill model to a specialty pharmacy approach, expanding patient access.

• Copay assistance program caps patient out-of-pocket at $25 for up to two applicators.

• Over 220 million lives now covered under medical or pharmacy benefit, with ongoing payer negotiations.

• Goal is broad dual coverage across all states by year-end, with quarterly progress updates.